drugset / Trial / NCT00292344

Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea

NCT00292344

RandomizedSingle-groupDouble-blindTreatment

Summary

Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment.

Timeline

Start
2004-06
Primary completion
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Loperamide Small molecule 2 mg
Subject Rifaximin Other / unclassified 200 mg

Indications